Kodiak Sciences/$KOD
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Kodiak Sciences
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
- Ticker
- $KOD
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 141
- Headquarters
- Palo Alto, United States
- Website
- kodiak.com
Kodiak Sciences Metrics
BasicAdvanced
$6.2B
-
-$4.18
2.20
-
Price and volume
Market cap
$6.2B
Beta
2.2
52-week high
$104.00
52-week low
$15.83
Average daily volume
2.9M
Financial strength
Current ratio
2.489
Quick ratio
2.386
Long term debt to equity
0.703
Total debt to equity
0.863
Profitability
EBITDA (TTM)
-230.978
Management effectiveness
Return on assets (TTM)
-60.45%
Return on equity (TTM)
-368.37%
Valuation
Price to book
101.79
Price to tangible book (TTM)
101.79
Price to free cash flow (TTM)
-35.944
Free cash flow yield (TTM)
-2.78%
Free cash flow per share (TTM)
-2.759
Growth
Earnings per share change (TTM)
10.13%
3-year earnings per share growth (CAGR)
-9.87%
What the Analysts think about Kodiak Sciences
Analyst ratings (Buy, Hold, Sell) for Kodiak Sciences stock.
Analyst projections of the future price of Kodiak Sciences stock.
Bulls say / Bears say
In DAYBREAK, Zenkuda matched aflibercept on one-year vision gains, while 54% of patients reached six-month dosing and median post-loading injections were one versus five. That could give it a clear treatment-burden advantage in wet AMD. (Retinal Physician)
In GLOW2, 62.5% of patients on Zenkuda achieved a two-step improvement in diabetic retinopathy severity at 48 weeks, versus 3.3% on sham; the study also reported fewer sight-threatening complications. This supports potential in a second retinal disease area. (Medscape)
KSI-501 met its one-year vision endpoint and an anatomical secondary endpoint in wet AMD. Its Phase 3 ALTO study is now testing the dual-pathway drug against aflibercept in diabetic macular oedema, offering another potential market opportunity. (Retinal Physician, Kodiak Sciences Inc.)
At June 30, Kodiak had $125.9 million in cash and reported a $65.6 million second-quarter net loss; it has since set up a $350 million at-the-market equity programme. Selling shares could extend its runway but dilute existing holders. (OTC Markets, Simply Wall St)
KSI-501 passed its non-inferiority test, but investigators still plan post-hoc analyses to identify which patients benefit from IL-6 inhibition. Its added value over VEGF-only treatment is therefore not yet established across the wider wet AMD population. (Retinal Physician)
Zenkuda still needs FDA approval, and DAYBREAK follow-up is continuing to week 96, so its longer-term profile and commercial prospects remain uncertain. The shares surged after the topline result, increasing the risk of disappointment if the eventual label or market uptake falls short. (Retinal Physician, BioSpace)
Data summarised monthly by Lightyear AI. Last updated on 25 Oct 2026.
Kodiak Sciences Financial Performance
Revenues and expenses
Kodiak Sciences Earnings Performance
Company profitability
Upcoming events
No upcoming events
Kodiak Sciences News
AllArticlesVideos
Kodiak Sciences' Two Wet AMD Treatments Match Aflibercept in Phase III Study
MarketBeat4 weeks ago
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Proactive Investors1 month ago
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Benzinga1 month ago
Funds containing Kodiak Sciences
Fund name | Fund size | $KOD weighting |
|---|---|---|
iShares Nasdaq US BiotechnologyÂŁBTEK | $1.1B | 0.40% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.40% |
SPDR Russell 2000 US Small CapÂŁR2SC | $5.3B | 0.13% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.13% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.